The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen
Clifford J
CJ
Maine Center for Osteoporosis, St. Joseph Hospital, Bangor, USA.
D026683:Advisory Committees; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D004341:Drug Evaluation / Q000592:standards; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D015201:Meta-Analysis as Topic; D017202:Myocardial Ischemia / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone